Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/1/2007 First Published: 10/1/1999


1.		Phase II/III Randomized Study of Leflunomide (SU101) With Mitoxantrone and Prednisone Versus Mitoxantrone and Prednisone Alone in Patients With Hormone Refractory Prostate Cancer (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.035 SUGEN-990711, NCT00004071

Last Modified: 5/17/2007 First Published: 6/1/1998


2.		Phase III Randomized Study of Leflunomide (SU101) Versus Procarbazine for Patients with Glioblastoma Multiforme in First Relapse (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.015 MSKCC-98020, UCLA-HSPC-980105201, NCT00003293

Last Modified: 7/1/1997


3.		Phase I/II Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) in Ovarian Cancer, non-Small Cell Lung Cancer, and Prostate Cancer (Summary Last Modified 07/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.004 NCI-V96-1091

Last Modified: 11/1/1999 First Published: 9/1/1998


4.		Phase II Study of Leflunomide (SU101) in Patients with Recurrent Stage III or IV Ovarian Cancer (Summary Last Modified 11/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.009 NYU-9828

Last Modified: 9/1/1999 First Published: 2/1/1999


5.		Phase II Study of Leflunomide (SU101) in Patients with Advanced Non-Small Cell Lung Cancer (Summary Last Modified 09/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.010

Last Modified: 5/1/2000 First Published: 4/1/1999


6.		Phase II Study of Leflunomide (SU101) in Patients with Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma in First Relapse (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				SUGEN-SU101.021 MSKCC-98111, NCI-G99-1506, NCT00003775

Last Modified: 7/1/1997


7.		Phase I Study of SU101 Administered by Four Weekly 24-Hour Infusions for Recurrent Malignant Gliomas (Summary Last Modified 07/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				MSKCC-95019 NCI-V95-0663

Last Modified: 8/1/1997


8.		Phase I Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) in Advanced Solid Malignancies (Summary Last Modified 08/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.002 NCI-V96-1090

Last Modified: 12/1/1997


9.		Phase I Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) Given Weekly Following a Loading Dose in Advanced Solid Malignancies (Summary Last Modified 12/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				SUGEN-SU101.003 NCI-V96-1092

Last Modified: 8/1/2000


10.		Phase I Study of Leflunomide (SU101) in Pediatric Patients with Refractory Malignancy (Summary Last Modified 08/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				3 to 21				NCI, Pharmaceutical / Industry				NCI-97-C-0087E SUGEN-NCI-97-C-0087

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute